2029 Chemotherapy FDA 
Pharmaceutical Technology
JULY 8, 2022
In December 2014, Amgen’s landmark FDA approval saw Blincyto (blinatumomab) approved for relapsed/refractory (R/R) B-cell progenitor acute lymphoblastic leukaemia (B-ALL), at the time being the only marketed BiTE. Currently, there are 110 BiTEs in oncology clinical trials, with seven in Phase III and three in pre-registration. months vs. 4.0
Roots Analysis
OCTOBER 4, 2023
During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 1, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Sign up for our daily news round-up!
Pharmaceutical Technology
JULY 8, 2025
Go deeper with GlobalData Reports LOA and PTSR Model - Efbemalenograstim Alfa La in Chemotherapy Indu. By GlobalData Learn more about Strategic Intelligence “Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029. How will RFK Jr’s American dream for vaccines play out?
Pharmaceutical Technology
JULY 4, 2025
Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!
Expert insights. Personalized for you.
59 
Let's personalize your content